Improvement of tumor localization of photosensitizers for photodynamic therapy and its application for tumor diagnosis

Current Topics in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 176-184

  Ogura, Shun Ichiro ^a   Hagiya, Yuichiro ^a   Tabata, Kenji ^a   Kamachi, Toshiaki ^a   Okura, Ichiro ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Aminolevulinic acid; Immunoconjugate; Photodynamic diagnosis; Photodynamic therapy; Phthalocyanine; Tumor marker

Indexed keywords

AMINOLEVULINIC ACID; CANCER ANTIBODY; HEMATOPORPHYRIN DERIVATIVE; IMMUNOGLOBULIN G; METALLOPORPHYRIN; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ZINC; PROTOPORPHYRIN; ROSTAPORFIN; TRANSFERRIN; TUMOR MARKER; TX 101A; TX 106A; UNCLASSIFIED DRUG; ZINC HEXADECAFLUOROPHTHALOCYANINE; ZINC OCTACARBOXYPHTHALOCYANINE; ZINC PHTHALOCYANINE TETRASULFONATE; ZINC TETRACARBOXYOCTAFLUOROPHTHALOCYANINE;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BINDING AFFINITY; BLADDER CANCER; BOWEN DISEASE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONJUGATION; DRUG ABSORPTION; DRUG CONJUGATION; DRUG SELECTIVITY; EPITHELIAL NONMELANOMA SKIN CANCER; FLUORESCENCE; FLUORESCENCE ANALYSIS; GLIOMA; HUMAN; HYDROPHOBICITY; LIPID MEMBRANE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SKIN CANCER; TRANSURETHRAL RESECTION; TUMOR LOCALIZATION; UTERUS CANCER;

HUMANS; METALLOPORPHYRINS; NEOPLASMS; ORGAN SPECIFICITY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84856466042     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799078883     Document Type: Article

References (71)

1. Ogura, S; Tabata, K.; Fukushima, K.; Kamachi, T.; Okura, I. Development of phthalocyanines for photodynamic therapy. J. Porphyr. Phthalocya., 2006, 10, 1116-1124.
2. Levy, J.G.; Obochi, M. New Applications in Photodynamic Therapy Introduction. Photochem. Photobiol., 1996, 64, 737-739.
3. Bonnett, R. Photodynamic therapy in historical perspective. Rev. Contemp. Pharmacother., 1999, 10, 1-17.
4. Milgrom, L.; MacRobert, S. Light years ahead. Chem. Br., 1998, 34, 45-50.
5. Bonnett, R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem. Soc. Rev., 1995, 24, 19-33.
6. Lipson, E.R.; Baldes, E.; Olsen, M.A. The use of a derivative of hematoporhyrin in tumor detection. J. Natl. Cancer Inst., 1961, 26, 1-11.
7. Diamond, I.; Granelli, S.G.; McDonaph, A.F.; Nielsen, S.; Wilson, C.B.; Jaenkcke, R. Photodynamic therapy of malignant tumours. Lancet, 1972, 2, 1175-1177.
8. Dougherty, J.T.; Lawrence, G.; Kaufman, E.J.; Boyle, D.; Weishaupt, R.K.; Goldfarb, A. Photoradiation in the treatment of recurrent breast carcinoma. J. Natl. Cancer Inst., 1979, 62, 231-237.
9. Philips, D. Chemical mechanisms in photodynamic therapy with phthalocyanines. Prog. React. Kinet., 1997, 22, 175-300.
10. Wilson, B.C. Photosensitizing Compounds 1989, Wiley, 60-77.
11. Rodal, G.H.; Rodal, S.K.; Moan, J.; Berg, K. Liposome-bound Zn(II)-phthalocyanine. Mechanisms for cellular uptake and photosensitization. J. Photochem. Photobiol. B, 1998, 45, 150-159.
12. van Leengoed, H.L.; van der Veen, N.; Versteeg, A.A.; Ouellet, R.; van Lier, J.E.; Star, W.M. In vivo fluorescence kinetics of phthalocyanines in a skin-fold observation chamber model: role of central metal ion and degree of sulfonation. Photochem. Photobiol., 1993, 58, 233-237.
13. He, J.; Larkin, H.E.; Li, Y.S.; Rihter, D.; Zaidi, S.I.; Rodgers, M.A.; Mukhtar, H.; Kenney, M.E.; Oleinick, N.L. The synthesis photophysical and photobiological properties and in vitro structureactivity relationships of a set of silicon phthalocyanine PDT photosensitizers. Photochem. Photobiol., 1997, 65, 581-586.
14. Mang, T.S.; Allison, R.; Hewson, G.; Snider, W.; Moskowitz, R. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J. Sci. Am., 1998, 4, 378-384.
15. Ciulla, T.A.; Criswell, M.H.; Snyder, W.J.; Small, W.T. Photodynamic therapy with PhotoPoint photosensitiser MV6401 indium chloride methyl pyropheophorbide achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Brit. J. Ophthalmol., 2005, 89, 113-119.
16. Verigos, K.; Stripp, D.C.; Mick, R.; Zhu, T.C.; Whittington, R.; Smith, D.; Dimofte, A.; Finlay, J.; Busch, T.M.; Tochner, Z.A.; Malkowicz, S.; Glatstein, E.; Hahn, S.M. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J. Environ. Pathol. Toxicol. Oncol., 2006, 25, 373-387.
17. Koudinova, N.V.; Pinthus, J.H.; Brandis, A.; Brenner, O.; Bendel, P.; Ramon, J.; Eshhar, Z.; Scherz, A.; Y. Salomon, Photodynamic therapy with Pd-bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int. J. Cancer, 2003, 104, 782-789.
18. Berdugo, M.; Bejjani, R.A.; Valamanesh, F.; Savoldelli, M.; Jeanny, J.C.; Blanc, D.; Ficheux, H.; Scherz, A.; Salomon, Y.; BenEzra, D.; Behar-Cohen, F. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest. Ophthalmol. Vis. Sci., 2008, 49, 1633-1644.
19. Fukushima, K.; Tabata, K.; Okura, I. Photochemical properties of water-soluble fluorinated zinc phthalocyanines and their photocytotoxicity against HeLa cells. J. Porphyr. Phthalocya., 1998, 2, 219-222.
20. Tabata, K.; Fukushima, K.; Oda, K.; Okura, I. Selective aggregation of zinc phthalocyanines in the skin. J. Porphyr. Phthalocya., 2000, 4, 278-284.
21. Oda K, Ogura S, Okura I. Preparation of a water-soluble fluorinated zinc phthalocyanine and its effect for photodynamic therapy. J. Photochem. Photobiol. B 2000, 59, 20-25.
22. Kennedy, J.C.; Pottier, R.H.; Pross, D.C. Photodynamic therapy with endogenous protoporphyrin. IX: Basic principles and present clinical experience. J. Photochem. Photobiol. B, 1990, 6, 143-148.
23. Kennedy, J.C.; Pottier, R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy J. Photochem. Photobiol. B, 1992, 14, 275-292.
24. Tabata, K.; Ogura, S.; Okura, I. Photodynamic efficiency of protoporphyrin IX: Comparison of endogenous protoporphyrin IX Induced by 5-Aminolevulinic Acid and exogenous porphyrin IX. Photochem. Photobiol., 1997, 66, 842-846.
25. Kochevar, I.E.; Lynch, M.C.; Zhuang, S.; Lambert, C.R. Singlet Oxygen, but not oxidizing radicals, induces apoptosis in HL-60 Cells. Photochem. Photobiol., 2000, 72, 548-553.
26. Kessel, D.; Luo, Y.; Deng, Y.; Chang, C.K. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem. Photobiol., 1997, 65, 422-426.
27. Zimmermann, H. W.; Cernay, T.H. Selective photosensitization of mitochondria by the lipophilic cationic porphyrin POR10. J. Photoch. Photobiol. B, 1996, 34, 191-196.
28. Lin, C. P.; Lynch, M. C.; Kochevar, I.E. Reactive oxidizing species produced near the plasma membrane induce apoptosis in bovine aorta endothelial cells. Exp. Cell Res., 2000, 259, 351-359.
29. Ricchelli, F.; Franchi, L.; Miotto, G.; Borsetto, L.; Gobbo, S.; Nikolov, P.; Bommer J.C.; Reddi, E. Meso-substituted tetra-cationic porphyrins photosensitize the death of human fibrosarcoma cells via lysossomal targeting. Int. J. Biochem. Cell B, 2005, 37, 306-319.
30. Morgan, J.; Lottman, H.; Abbou, C.C.; Chopin, D.K. A comparison of direct and liposomal antibody conjugates of sulfonated aluminum phthalocyanines for selective photoimmunotherapy of human bladder carcinoma. Photochem. Photobiol. 1994, 60, 486-496.
31. Carcenac, M.; Larroque, C.; Langlois, R.; Van Lier, J.E.; Artus, J.-C.; Pèlegrin, A. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibodyphthalocyanine conjugates. Photochem. Photobiol., 1999, 70, 930-936.
32. Vrouenraets, M.B.; Visser, G.W.M.; Stigter, M.; Oppelaar, H.; Snow, G.B.; Van Dongen, G.A.M.S. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: Improved efficacy in photodynamic therapy. Cancer Res., 2001, 61, 1970-1975.
33. Ogura, S.; Fujita, Y.; Kamachi, T.; Okura, I. Preparation of chlorin e6-monoclonal antibody conjugate and its effect for photodynamic therapy. J. Porphyr. Phthalocya., 2001, 5, 486-489.
34. Hirohara, S.; Obata, M.; Saito, A.; Ogata, S.; Ohtsuki, C.; Higashida, S.; Ogura, S.; Okura, I.; Sugai, Y.; Mikata, Y.; Tanihara, M.; Yano S. Cellular uptake and photocytotoxicity of glycoconjugated porphyrins in HeLa cells. Photochem. Photobiol., 2004, 80, 301-308.
35. Hirohara, S.; Obata, M.; Ogata, S.; Ohtsuki, C.; Higashida, S.; Ogura, S.; Okura, I.; Takenaka, M.; Ono, H.; Sugai, Y.; Mikata, Y.; Tanihara, M.; Yano, S. Cellular uptake and photocytotoxicity of glycoconjugated chlorins in HeLa cells. J. Photochem. Photobiol. B, 2005, 78, 7-15.
36. Hirohara, S.; Obata, M.; Ogata, S.; Kajiwara, K.; Ohtsuki, C.; Tanihara, M.; Yano, S. Sugar-dependent aggregation of glycoconjugated chlorins and its effect on photocytotoxicity in HeLa cells. J. Photochem. Photobiol. B, 2006, 84, 56-63.
37. Obata, M.; Hirohara, S.; Sharyo, K.; Alitomo, H.; Kajiwara, K.; Ogata, S.; Tanihara, M.; Ohtsuki, C.; Yano, S. Sugar-dependent photodynamic effect of glycoconjugated porphyrins: A study on photocytotoxicity, photophysical properties and binding behavior to bovine serum albumin (BSA). Biochim. Biophys. Acta, 2007, 1770, 1204-1211.
38. Hirohara, S.; Obata, M.; Alitomo, H.; Sharyo, K.; Ogata, S.; Ohtsuki, C.; Yano, S.; Ando, T.; Tanihara, M.; Structurephotodynamic effect relationships of 24 glycoconjugated photosensitizers in HeLa Cells. Biol. Pharm. Bull., 2008, 31, 2265-2272.
39. Chernonosov, A.A.; Kuznetsov, N.A.; Koval, V.V.; Pyshnyi, D.V.; Derkacheva, N.M.; Lukyanets, E.A.; Fedorova, O.S. Thermodynamics of interaction of phthalocyanine-oligonucleotide conjugates with single-and double-stranded DNA, nucleosides. Nucleosides Nucleotides Nucleic Acids, 2004, 23, 983-987.
40. Chernonosov, A.A. Phthalocyanine conjugates of oligonucleotides as new reagents for sensitized and catalytic modification of DNA and DNA-binding proteins. FEBS J., 2005, 272, 542-543.
41. Severin, S.E.; Posypanova, G.A.; Katukov, V.Y.; Shmyrev, I.I.; Luzhkov, Y.M.; Gerasimova, G.K.; Zhukova, O.S.; Vorozhtsov, G.N.; Kaliya, O.L.; Lukyanets, E.A.; Severin, E.S. Antitumor activity of conjugates of the oncofetal protein R-fetoprotein and phthalocyanines in vitro. Biochem. Mol. Biol. Int., 1997, 43, 873-881.
42. Brasseur, N.; Langlois, R.; La Madeleine, C.; Ouellet, R.; van Lier, J.E. Receptor-mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin. Photochem. Photobiol., 1999, 69, 345-352.
43. Ogunsipe, A.; Nyokong, T. Photophysicochemical consequences of bovine serum albumin binding to non-transition metal phthalocyanine sulfonates. Photochem. Photobiol. Sci., 2005, 4, 510-516.
44. Huang, J.D.; Lo, P.C.; Chen, Y.M.; Lai, J.C.; Fong, W.P.; Ng, D.K.P. (2006) Preparation and in vitro photodynamic activity of novel silicon (IV) phthalocyanines conjugated to serum albumins. J. Inorg. Biochem., 2006, 100, 946-951.
45. Sibrian-Vazquez, M.; Ortiz, J.; Nesterova, I. V.; Fernandez-Lazaro, F.; Sastre-Santos, A.; Soper, S. A.; H. Vicente, M. G. Synthesis and properties of cell-targeted Zn(II)-phthalocyanine-peptide conjugates. Bioconjugate Chem., 2007, 18, 410-420.
46. Kralova, J.; Synytsya, A.; Pouckova, P.; Koc, M.; Dvorak, M.; Kral, V. Novel porphyrin conjugates with a potent photodynamic antitumor effect: Differential efficacy of mono-and bis-betacyclodextrin derivatives in vitro and in vivo. Photochem. Photobiol., 2006, 82, 432-438.
47. Savitsky, A.A.; Gukasova, N.V.; Gumanov, S.G.; Feldman, N.B.; Luk'yanets, E.A.; Mironov, A.F.; Yakubovskaya, R.I.; Lutsenko, S.V.; Severin, S.E. Cytotoxic action of conjugates of R-fetoproteinand epidermal growth factor with photoheme, chlorines, and phthalocyanines. Biochemistry (Moscow), 2000, 65, 732-736.
48. Gijsens, A.; Derycke, A.; Missiaen, L.; Vos, D.D.; Huwyler, J.; Eberle, A.; Witte, D.P. Targeting of the photocytotoxic compound A1PcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int. J. Cancer, 2002, 101, 78-85.
49. Roberts, G.W.; Berns, W.M. In vitro photosensitization. I. Cellular uptake and subcellular localization of mono-L-aspartyl chlorin e6, chloro-aluminum sulfonated phthalocyanine, and photofrin II. Lasers Surg. Med., 1989, 9, 90-101.
50. Bachor, R.; Shea, R.C.; Gillies, R.; Hassan, T. Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc. Natl. Acad. Sci. USA, 1991, 88, 1580-1584.
51. Wiseman, H.; Halliwell, B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem. J., 1996, 313, 17-29.
52. Ogura, S.; Yazaki, K.; Yamaguchi, K.; Kamachi, T.; Okura, I. Localization of poly-L-lysine-photosensitizer conjugate in nucleus. J. Control. Release, 2005, 103, 1-6.
53. Krammer, B.; Plaetzer, K. ALA and its clinical impact, from bench to bedside. Photochem. Photobiol. Sci., 2008, 7, 283-289.
54. Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol., 2006, 7, 392-401.
55. Roberts, D.W.; Valdés, P.A.; Harris, B.T.; Fontaine, K.M.; Hartov, A.; Fan, X.; Ji, S.; Lollis, S.S.; Pogue, B.W.; Leblond, F.; Tosteson, T.D.; Wilson, B.C.; Paulsen, K.D. Coregistered fluorescenceenhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J. Neurosurg., 2010, 114(3), 595-603.
56. Lacroix, M.; Abi-Said, D.; Fourney, D.R.; Gokaslan, Z.L.; Shi, W.; DeMonte, F.; Lang, F.F.; McCutcheon, I.E.; Hassenbusch, S.J.; Holland, E.; Hess, K.; Michael, C.; Miller, D.; Sawaya, R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg., 2001, 95, 190-198.
57. Stummer, W.; Novotny, A.; Stepp, H.; Goetz, C.; Bise, K.; Reulen, H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg., 2000, 93, 1003-1013.
58. Claydon, P.E.; Ackroyd, R. 5-Aminolaevulinic acid-induced photodynamic therapy and photodetection in Barrett's esophagus. Dis. Esophagus., 2004, 17, 205-212.
59. Endlicher, E.; Knuechel, R.; Hauser, T.; Szeimies, R.M.; Schölmerich, J.; Messmann, H. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut, 2001, 48, 314-319.
60. Haringsma, J. Barrett's oesophagus: new diagnostic and therapeutic techniques. Scand J. Gastroenterol Suppl., 2002, 236, 9-14.
61. Wilby, D.; Thomas, K.; Ray, E.; Chappell, B.; O'Brien, T. Bladder cancer: new TUR techniques. World J. Urol., 2009, 27, 309-312.
62. Cookson, M.S.; Herr, H.W.; Zhang, Z.F.; Soloway, S.; Sogani, P.C.; Fair, W.R. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol., 1997, 158, 62-67.
63. Lee, R.; Droller, M.J. The natural history of bladder cancer. Implications for therapy. Urol. Clin. N. Am., 2000, 27, 1-13.
64. Schulze, M.; Stotz, N.; Rassweiler, J. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach. J. Endourol., 2007, 21, 1533-1541.
65. Filbeck, T.; Pichlmeier, U.; Knuechel, R.; Wieland, W.F.; Roessler, W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J. Urol., 2002, 168, 67-71.
66. Babjuk, M.; Soukup, V.; Petrík, R.; Jirsa, M.; Dvorácek, J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int., 2005, 96, 798-802.
67. Collinet, P.; Delemer, M.; Jouve, E.; Regis, C.; Farine, M. O.; Vinatier, D.; Cosson, M.; Serge Mordon, S. Fluorescence diagnosis of cervical squamous intraepithelial lesions: A clinical feasability study. Photodiagnosis Photodyn. Ther., 2007, 4, 112-116.
68. Allison, R.R.; Cuenca, R.; Downie, G.H.; Randall, M.E.; Bagnato, V.S.; Sibata C.H. PD/PDT for gynecological disease: A clinical review. Photodiagnosis Photodyn. Ther., 2005, 2, 51-63.
69. Braathen, L.R.; Szeimies, R.M.; Basset-Seguin, N.; Bissonnette, R.; Foley, P.; Pariser, D.; Roelandts, R.; Wennberg, A. M.; Morton, C. A. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J. Am. Acad. Dermatol., 2007, 56, 125-143.
70. A. Sidoroff, A.; Thaler, P. Taking treatment decisions in nonmelanoma skin cancer-The place for topical photodynamic therapy (PDT). Photodiagnosis Photodyn. Ther., 2010, 7, 24-32.
71. Ogura, S.; Ishizuka, M.; Mizokami, Y.; Honda, K.; Tabata, K.; Kamachi, T.; Mochizuki, T.; Okura, I. Analysis of porphyrins in mouse plasma after administration of 5-aminolevulinic acid as a potential tumor marker, Porphyrins,2009, 18, 25-30.